Assessment of a close respiratory follow-up schedule at 3 and 6 months after acute COVID-19 and its related investigations.


Journal

Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438

Informations de publication

Date de publication:
10 2023
Historique:
received: 24 02 2023
revised: 17 07 2023
accepted: 19 07 2023
medline: 16 8 2023
pubmed: 22 7 2023
entrez: 21 7 2023
Statut: ppublish

Résumé

Respiratory sequela after acute COVID-19 is common and requires medical follow-up. Considering its vast economic impact, there is still no consensus regarding the mid-term follow-up plan after recovery. To evaluate the necessity of a close pulmonary follow-up schedule after acute COVID-19 and its related investigations. A prospective cohort study including adult patients after acute COVID-19 pneumonia. Patients were invited or referred to a 3- and 6-month follow-up visits at a large pulmonary institute in a tertiary center. Before each visit, patients completed demographic and clinical questionnaires, pulmonary function tests (PFTs), and chest CT scans. 168 patients were included after completing both visits (medians of 80 and 177 days). Their mean age was 58 ± 15 and 52% recovered from severe or critical COVID-19. Between the two visits, there was no change in DLCOc (mean 73 ± 18 %predicted in both visits) and FVC (mean 90 ± 16 vs. 89 ± 16 %predicted). The COPD assessment tool and modified Medical Research Council scale had inverse correlations with the DLCOc, and similarly did not change between the visits. Occupational exposures were the only factor associated with a change in DLCOc during follow-up (3% decrease, p = 0.04). An improvement in chest CT findings at the second visit was not associated with a change in PFTs. Most clinical variables did not change during a close follow-up schedule in the first six months after acute COVID-19. Such a follow-up plan does not appear necessary and should be personalized to limit excessive costs and resources.

Sections du résumé

BACKGROUND
Respiratory sequela after acute COVID-19 is common and requires medical follow-up. Considering its vast economic impact, there is still no consensus regarding the mid-term follow-up plan after recovery.
OBJECTIVE
To evaluate the necessity of a close pulmonary follow-up schedule after acute COVID-19 and its related investigations.
METHODS
A prospective cohort study including adult patients after acute COVID-19 pneumonia. Patients were invited or referred to a 3- and 6-month follow-up visits at a large pulmonary institute in a tertiary center. Before each visit, patients completed demographic and clinical questionnaires, pulmonary function tests (PFTs), and chest CT scans.
RESULTS
168 patients were included after completing both visits (medians of 80 and 177 days). Their mean age was 58 ± 15 and 52% recovered from severe or critical COVID-19. Between the two visits, there was no change in DLCOc (mean 73 ± 18 %predicted in both visits) and FVC (mean 90 ± 16 vs. 89 ± 16 %predicted). The COPD assessment tool and modified Medical Research Council scale had inverse correlations with the DLCOc, and similarly did not change between the visits. Occupational exposures were the only factor associated with a change in DLCOc during follow-up (3% decrease, p = 0.04). An improvement in chest CT findings at the second visit was not associated with a change in PFTs.
CONCLUSIONS
Most clinical variables did not change during a close follow-up schedule in the first six months after acute COVID-19. Such a follow-up plan does not appear necessary and should be personalized to limit excessive costs and resources.

Identifiants

pubmed: 37479120
pii: S0954-6111(23)00255-X
doi: 10.1016/j.rmed.2023.107367
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107367

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ophir Freund (O)

The Institute of Pulmonary Medicine, Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: ophir068@gmail.com.

Anna Breslavsky (A)

Division of Pulmonary Medicine, Barzilai Medical Center, Ashkelon, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Rotem Givoli-Vilensky (R)

Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Nadav Zacks (N)

Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Evgeni Gershman (E)

The Institute of Pulmonary Medicine, Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Ariel Melloul (A)

The Institute of Pulmonary Medicine, Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Ori Wand (O)

Division of Pulmonary Medicine, Barzilai Medical Center, Ashkelon, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Natalya Bilenko (N)

Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Medical Office of Southern District, Ministry of Health, Ashkelon, Israel.

Amir Bar-Shai (A)

The Institute of Pulmonary Medicine, Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH